Pfizer Inc. PFE on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as ...

In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

Pfizer (PFE) on Tuesday announced a successful late-stage trial outcome for its multiple myeloma therapy, Elrexfio (elranatamab), when used in an earlier-line setting against the hematological cancer.

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

Pfizer Inc. sees a path forward for an experimental lung cancer drug in combination with other medicines, despite it failing a key clinical trial.

Pfizer Inc. (PFE) stock currently trades at roughly half the high it closed at in December 2021. Many shareholders still ...

Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash ...

Pfizer’s Jeff Legos discusses how science, AI and patient insights are shaping cancer research and the next generation of ...

About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA ...

One of these pharma stocks offers more income, but the other offers a safer dividend.

Pfizer (PFE) said Tuesday that the phase 3 MagnetisMM-32 study of Elrexfio in adults with relapsed or refractory multiple myeloma met its primary endpoint of progression-free surv ...